[Morphological study of the myocardium of mice infected with Coxsackie B1 virus during the treatment with an immunomodulating drug T-activin]. / Morfologicheskoe izuchenie miokarda myshei, infitsirovannykh virusom Koksaki B1, na fone lecheniia immunomoduliruiushchim preparatom T-aktivinom.

The study was undertaken to examine myocardial morphological alterations in mice treated with T-activin in different periods of viral myocarditis. Two-month BALB/C mice of both sexes were used in the experiments, which were intraperitoneally given 0.2 ml Coxsackie B1 virus in a titer of 10(-3)-10(-7) D50 ml. The material was taken 3, 5, 7, 9, 15, and 30 days following infection. Intact mice and animals given culture fluid were applied as controls. T-activin was subcutaneously injected in a dose of 0.2 ml at the rate of 0.01 mg per kg body weight on day 5 after virus infection for 5 days. The predominance of an alterative component of inflammation (dystrophic, necrobiotic and necrotic changes) over proliferative processes was ascertained to be common to all periods of infection. T-activin administration attenuated myocardial damage.

[The efficacy of taktivin in patients with viral myocarditis and dilated cardiomyopathy]. / Effektivnost' taktivina u bol'nykh virusnym miokarditom i dilatatsionnoi kardiomiopatiei.

The aim of the present research was to study the efficacy of the immunomodulating agent T-activin in patients with viral myocarditis and dilated cardiomyopathy (DCMP). The data obtained indicate that under the influence of the general therapy with T-activin cellular immunity manifested positive changes and the patients with viral myocarditis and DCMP felt better.

[Effects of T-activin in viral myocarditis in animal experiments]. / Vliianie T-aktivina na virusnyi miokardit v éksperimente.

The efficacy of immunomodulating agent T-activin has been studied in adult BALB/C mice infected with Coxsackie B1 virus. Optical, electron microscopic and immunological tests have shown that T-activin protects myocardium and modulates immune disorders in mice with viral myocarditis.

[Hydrochlorides of N-hydroxyalkyl-alpha-piperidine carboxylic arylamides possessing antiarrhythmic activity]. / Khlorgidraty nekotorykh arilamidov N-oksialkil-al'fa-piperidinkarbonovykh kislot, obladaiushchie antiaritmicheskoi aktivnost'iu.

It has been demonstrated in experimental arrhythmias of animals (aconitine one in rats, strophanthine in guinea-pigs, creation of an "ectopic focus of excitation" in cats by electric stimulation) that new compounds, the derivatives of piperidine carboxylic acids, possess antiarrhythmic activity. In doses of 6-23 mg/kg, the compounds under study prevented the development of the mixed type arrhythmia induced by intravenous injection of aconitine, prolonged the time of survival and prevented the animals' death during intravenous injection of the arrhythmogenic doses of strophanthine, prolonged the refractory period, and increased the threshold of ventricular fibrillation in cats. As regards the power of the antiarrhythmic effect, the compounds under study--hydrochlorides of arylamides of N-hydroxyalkly-alpha-piperidine carboxylic acids--approach lidocaine, yield to marcaine, and exhibit a broader range of therapeutic action.

[Analysis of the mechanisms of the anti-arrhythmic action of marcaine and lidocaine]. / K analizu mekhanizmov protivoaritmicheskogo deistviiia markaina i lidokaina.

It has been demonstrated in experiments on anesthetized cats with heart rhythm abnormalities induced by the creation of an "ectopic focus" by high-frequency electric stimulation of the ventricles that lidocaine in a dose of 5.8 mg/kg is inferior to marcaine in a dose of 1.3 mg/kg as regards the ability to inhibit the sympathetic tone. Lidocaine and marcaine have been discovered to produce different effects: lidocaine produced a dose-dependent selective inhibition of C-components of reflex discharges, whereas marcaine a more prolonged and uniform suppression of both A- and C-components of evoked responses, inhibiting both excitatory and inhibitory components of reflex responses.

[Anti-arrhythmia properties of marcaine]. / K voprosu ob antiaritmicheskikh svoistvakh markaina.

Comparative study of antiarrhythmic properties of marcaine and lidocaine was made on aconitine- and strophanthine-induced experimental arrhythmias and in rhythm disorders induced by electrical stimulation of the ventricles. Marcaine (5 mg/kg) prevented the development of rhythm disorders induced in rats by intravenous injection of aconitine (40 micrograms/kg) and also raised the arrhythmogenic dose of strophanthine (ouabain) in guinea-pigs. Administration of marcaine to anesthetized cats in a dose of 2 mg/kg reduced the assimilation of the rhythm imposed on the heart ventricles at the expense of an increase in the effective refractory period and increased the threshold of electrical fibrillation of the ventricles more noticeably and for a longer time as compared with lidocaine administered in a dose of 5 mg/kg. Marcaine compares very favourably with lidocaine as regards the potency and duration of the antiarrhythmic effect. However, it is inferior to lidocaine from the standpoint of the therapeutic action range. Toxic effects of marcaine do not make clear the prospects of its clinical use as an antiarrhythmic drug. Nevertheless the search of new effective antiarrhythmic drugs among marcaine analogs holds promise.